Granite Investment Partners Llc decreased Supernus Pharmaceuticals Inc (SUPN) stake by 23.15% reported in 2017Q3 SEC filing. Granite Investment Partners Llc sold 111,808 shares as Supernus Pharmaceuticals Inc (SUPN)’s stock rose 29.12%. The Granite Investment Partners Llc holds 371,154 shares with $14.85 million value, down from 482,962 last quarter. Supernus Pharmaceuticals Inc now has $2.30B valuation. The stock increased 3.53% or $1.53 during the last trading session, reaching $44.7. About 1.10 million shares traded or 60.98% up from the average. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 91.80% since March 17, 2017 and is uptrending. It has outperformed by 75.10% the S&P500.
NOVOZYMES A/S ORDINARY SHARES (OTCMKTS:NVZMF) had a decrease of 21.85% in short interest. NVZMF’s SI was 569,900 shares in March as released by FINRA. Its down 21.85% from 729,200 shares previously. With 900 avg volume, 633 days are for NOVOZYMES A/S ORDINARY SHARES (OTCMKTS:NVZMF)’s short sellers to cover NVZMF’s short positions. The SI to NOVOZYMES A/S ORDINARY SHARES’s float is 0.25%. The stock increased 0.41% or $0.22 during the last trading session, reaching $52.55. About 91 shares traded. Novozymes A/S (OTCMKTS:NVZMF) has 0.00% since March 17, 2017 and is . It has underperformed by 16.70% the S&P500.
Investors sentiment increased to 1.1 in 2017 Q3. Its up 0.12, from 0.98 in 2017Q2. It increased, as 22 investors sold SUPN shares while 97 reduced holdings. 42 funds opened positions while 75 raised stakes. 48.75 million shares or 3.64% more from 47.04 million shares in 2017Q2 were reported. U S Glob Invsts holds 0.47% or 32,000 shares. Farmers & Merchants Invs invested in 239 shares. Fiera Capital Corporation has invested 0.2% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Manufacturers Life Insur The reported 36,115 shares. Amer International Gru holds 37,920 shares or 0.01% of its portfolio. Moreover, Lpl Ltd Limited Liability Company has 0% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Aperio Grp Ltd Co has invested 0% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Citigroup invested in 140,095 shares. Panagora Asset Management stated it has 266,655 shares. Fmr Lc accumulated 65,900 shares. First Mercantile Tru Commerce stated it has 0.05% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). California Pub Employees Retirement System owns 0% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 47,090 shares. Neuberger Berman Group Incorporated Llc has invested 0% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Barclays Public Ltd Company accumulated 3,308 shares or 0% of the stock. Cortina Asset Ltd Liability Company holds 0.15% or 93,600 shares in its portfolio.
Granite Investment Partners Llc increased Re Max Hldgs Inc (NYSE:RMAX) stake by 10,470 shares to 177,265 valued at $11.27M in 2017Q3. It also upped Chart Inds Inc stake by 16,496 shares and now owns 286,758 shares. Acxiom Corp (NASDAQ:ACXM) was raised too.
Analysts await Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report earnings on May, 8. They expect $0.34 earnings per share, up 78.95% or $0.15 from last year’s $0.19 per share. SUPN’s profit will be $17.52 million for 32.87 P/E if the $0.34 EPS becomes a reality. After $0.44 actual earnings per share reported by Supernus Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -22.73% negative EPS growth.
Among 11 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Supernus Pharmaceuticals had 38 analyst reports since August 26, 2015 according to SRatingsIntel. The stock has “Buy” rating by Janney Capital on Monday, December 4. Stifel Nicolaus upgraded the shares of SUPN in report on Wednesday, November 8 to “Buy” rating. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, September 1. The firm earned “Buy” rating on Monday, November 20 by FBR Capital. The stock has “Neutral” rating by Piper Jaffray on Monday, July 18. Cowen & Co maintained the shares of SUPN in report on Tuesday, September 19 with “Buy” rating. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Hold” rating given on Wednesday, August 26 by Zacks. The rating was downgraded by Stifel Nicolaus on Tuesday, September 19 to “Hold”. Stifel Nicolaus maintained the stock with “Hold” rating in Friday, October 20 report. Cantor Fitzgerald maintained it with “Buy” rating and $4900 target in Wednesday, July 5 report.
Since January 2, 2018, it had 0 insider purchases, and 7 insider sales for $8.26 million activity. PATRICK GREGORY S also sold $2.18M worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Thursday, January 11. Vaughn Victor also sold $630,650 worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shares. 20,000 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shares with value of $899,500 were sold by Bhatt Padmanabh P..
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company has market cap of $15.44 billion. It operates in three divisions: Household Care & Technical, Agriculture & Bioenergy, and Food & Beverages. It has a 30.32 P/E ratio. The firm offers enzymes for use in household care products, such as laundry detergents, hand and automatic dishwashing soaps, and professional cleaning products.